More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$5.20B
EPS
0.71
P/E ratio
14.2
Price to sales
1.17
Dividend yield
3.343%
Beta
1.016558
Previous close
$6.48
Today's open
$6.46
Day's range
$6.45 - $6.63
52 week range
$6.25 - $8.94
show more
CEO
James D. DeVries
Employees
12200
Headquarters
Boca Raton, Florida
Exchange
New York Stock Exchange
Shares outstanding
789694313
Issue type
Common Stock
Industrials
Corporate Services
ADT Earns Two 2026 Buyer's Choice Awards from ConsumerAffairs, Based on Customer Reviews
BOCA RATON, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT), the leader in smart home security solutions, has earned two 2026 Buyer's Choice Awards from ConsumerAffairs, a leading platform for verified consumer reviews.
GlobeNewsWire • Jun 18, 2026

Should Value Investors Buy ADT (ADT) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research • Jun 17, 2026

ADT Joins Board of Directors of the Connectivity Standards Alliance, Reinforcing Its Role in Shaping the Future of the Connected Home
BOCA RATON, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT), the leader in smart home security solutions, today announced it has joined the Board of Directors of the Connectivity Standards Alliance (CSA), the global organization behind Matter, Zigbee and Aliro, foundational standards shaping the future of connected living.
GlobeNewsWire • Jun 17, 2026

Buy 2 Ideal June DiviDogs Per Barron's April To June Picks
Barron's April–June 2026 stock picks highlight 32 names, with a focus on 19 high-yield, dividend-paying equities subjected to contrarian 'dogcatcher' analysis. Top ten dividend stocks yield 1.33%–5.16%, with Build-A-Bear (BBW) and Kingstone (KINS) showing standout projected returns of 82.16% and 239.6%, respectively. CBL & Associates (CBL) and ADT Inc. (ADT) are identified as 'safer' ideal dividend dogs, with dividends from $1K invested exceeding their share prices.
Seeking Alpha • Jun 10, 2026

Are Investors Undervaluing ADT (ADT) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research • Jun 1, 2026

ADT (ADT) Upgraded to Buy: Here's Why
ADT (ADT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research • May 28, 2026

ADT Announces Yet Another DIY Home Security Line, Now With AI Features
ADT Blu shouldn't be confused with Blue by ADT, or ADT Self Setup. I know, it's a mess.
CNET • May 21, 2026

ADT Has A Clear AI-Driven Future (Rating Upgrade)
ADT becomes a more attractive investment following Apollo's complete exit and significant share repurchases. Despite flat revenue and EPS guidance in 2026, ADT targets a 5% revenue and 10% EPS CAGR, leveraging AI and the Origin AI acquisition for operational improvements and differentiation. My updated DCF values ADT at $10.33 per share, indicating a 50% undervaluation with an 8.5% shareholder yield.
Seeking Alpha • May 16, 2026

Is ADT (ADT) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research • May 15, 2026

AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
WHIPPANY, N.J.--(BUSINESS WIRE)--AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with mCSPC.
Business Wire • May 15, 2026

¹ Disclosures

Open an M1 investment account to buy and sell ADT Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.